Mar. 9 at 10:41 PM
$WINT - During Jed Latkin's leadership tenures, the stock prices of his associated companies have generally experienced significant declines, though the extent varies by firm.
Navidea Biopharmaceuticals (CEO/CFO/COO, 2016–2021):
The stock price experienced a steep downward trajectory during his five-year tenure.
In early 2016, the stock traded around
$22.60; by his resignation in October 2021, it had fallen to approximately
$1.82, a decline of over 90%.
ProPhase Labs (COO/Finance Head, Jan 2023 – Feb 2025):
The stock value saw continuous annual declines during this period.
The price fell -52.77% in 2023 and -83.62% in 2024.
By the time he departed in February 2025, the market capitalization had shrunk from over
$81 million (Dec 2023) to roughly
$8 million.
Windtree Therapeutics (CEO, Dec 2024 – Present):
Windtree has faced extreme volatility and a precipitous drop in value.
The stock plummeted by -99.99%....